Obesity Treatment Elbląg

Obesity is classified as E66 in ICD-10. The Polish Society for the Treatment of Obesity (PTLO) describes it in its 2024 guidelines as a chronic disease with a tendency to relapse. Fat tissue releases leptin, a hormone involved in satiety; the response to this signal can be weaker in obesity. After weight loss, hunger and energy-saving adaptations can make the result harder to maintain. Regain is not an inevitable outcome of every diet.

What influences the development of obesity?

Obesity is an excessive build-up of body fat that harms health. It develops when, over years, the energy from meals exceeds the energy the body uses. At first the fat cells grow in size, and later their number increases. Besides leptin, fat tissue releases substances that sustain chronic inflammation and reduce the sensitivity of tissues to insulin. Visceral fat, stored around the abdominal organs, has the strongest effect of this kind.

Genes largely determine the tendency to gain weight: twin studies attribute 40 to 70 percent of the differences in body weight between people to genes, and obesity often runs through several generations of one family. This tendency shows itself when high-calorie food is easy to get and work and commuting are spent sitting down. Lack of sleep, long-term stress and shift work also promote weight gain. Body weight also rises after quitting smoking, and in many women after pregnancy and during menopause. An underactive thyroid promotes weight gain, although it usually does not explain the whole of a person's obesity. We list the medicines that can promote weight gain in the section on tests.

Why does fat settle around the abdomen during menopause?

Oestrogen influences fat distribution. During menopause, more fat tends to accumulate around the abdomen, including between abdominal organs. SWAN found faster fat gain and loss of lean mass, which includes muscle, without faster overall weight gain. A similar number on the scales can therefore conceal a change in body composition and a larger waist. These changes vary between women.

What does obesity treatment consist of?

Treatment includes diagnosing obesity and related conditions, changing eating habits, physical activity and medication when indicated. Check-ups assess effectiveness and tolerability. A dietitian helps plan meals, while a psychodietitian (a dietitian trained in the psychology of eating) addresses emotional eating. During and after menopause we also consider muscle, bone health and cancer prevention for women.

BMI is body weight in kilograms divided by height in metres squared. A woman who is 162 cm tall and weighs 84 kg has a BMI of about 32. In the adult classification, overweight begins at 25, class I obesity at 30, class II at 35 and class III at 40. BMI does not show fat distribution or muscle mass, so we assess waist circumference and health as well.

Waist circumference is measured at the end of a breath out, halfway between the lowest rib and the top of the hip bone. Under International Diabetes Federation criteria, the thresholds for abdominal obesity in people of European ancestry are 80 cm for women and 94 cm for men, including those with a normal BMI. Visceral fat is associated with greater metabolic risk. For a woman whose BMI has risen from 24 to 27 and whose waist measures 92 cm, blood glucose, blood pressure and lipids merit assessment.

We ask how weight has changed since youth, after pregnancies and during menopause. The last menstrual period, sleep, snoring, hot flushes, medicines, alcohol and binge eating are relevant. These details help guide treatment beyond calculating an index.

When can obesity medication be started?

For many of the medicines discussed here, a BMI of at least 30 meets the weight criterion. At a BMI from 27 to below 30, a relevant weight-related condition is required, such as prediabetes, type 2 diabetes, hypertension, lipid disorders or sleep apnoea. The threshold alone does not guarantee a prescription: the doctor considers indications, contraindications, other medicines and overall health. Xenical has separate criteria: BMI at least 30, or above 28 with risk factors. Insulin resistance is not another name for prediabetes.

Below a BMI of 27, the usual weight-management indications for these medicines are not met. Nutritional treatment, exercise and investigation of symptoms remain appropriate. In older women we assess nutrition, function and bone health. Saxenda is not recommended from age 75; evidence for Wegovy and Mounjaro is limited from age 85. There is no single age limit or dose-adjustment rule for every medicine.

We treat obesity in an online programme. It lasts six months and costs PLN 1,799, and the patient buys the medicine separately at a pharmacy with an e-prescription. Before the first consultation, the patient measures weight, waist circumference and blood pressure at home. On the basis of the history and results, the doctor decides whether the patient can be treated in the programme. The price includes two 30-minute doctor consultations, two 40-50-minute online consultations with a psychologist and five medical reviews of app data without a call. The patient books the video consultations in the Nasz Gabinet app. The dates are counted from the initial consultation.

The price also includes an AI assistant and monitoring of body weight and treatment progress.

Once a week the patient records their weight in the app, and once a month their body measurements. After the injection, they also take a photo of the pen. The medical team looks at the photo. Before each check-up, the doctor reviews the patient's results. PTLO recommends that obesity treatment last at least a year, so after the programme a continuation package is available: 3 months for PLN 350. The package does not include video consultations, and the patient receives an e-prescription every month after a medical review.

Early check-ups focus on tolerability, appetite, nutrition and weight changes. Dose increases follow the rules for the particular medicine, rather than a shared calendar. We also agree on a manageable activity plan, including strengthening exercises. Later check-ups consider test results, other conditions and the need to adjust other medicines. The timing of effectiveness assessment depends on the product; not every medicine must be changed at six months or used at its highest dose. We regularly assess the need for continued treatment. A year of therapy does not mean that medication must stop.

How do we account for menopause and treatment safety?

• Menopausal hormone therapy can relieve troublesome menopausal symptoms. Starting, changing or stopping it is a decision for the clinician managing it, usually a gynaecologist. We do not offer hormones as a weight-loss treatment.
• Postmenopausal bleeding and a palpable breast lump need prompt investigation. The doctor determines the next steps and the safety of medication. An overdue screening mammogram alone is not a contraindication shared by all obesity medicines.
• This page concerns adults; some products also have paediatric indications requiring a separate assessment. Obesity medicines are not used during pregnancy. Wegovy and Saxenda should not be used during breastfeeding, whereas current Mounjaro product information allows treatment to be considered individually. Effective contraception is needed when pregnancy is possible. In agreement with the doctor, semaglutide must be stopped at least 2 months and tirzepatide at least one month before planned conception.

Before treatment, the doctor reviews previous results and chooses tests according to symptoms and medical conditions. You do not need to arrange a full panel yourself before the first consultation. Fasting glucose and HbA1c, reflecting average blood glucose over about 2 to 3 months, are commonly considered to assess glucose regulation. A lipid profile measures cholesterol and triglycerides; lipid metabolism can change after menopause. Creatinine and eGFR help assess kidney function. Liraglutide and Wegovy are not recommended in severe renal impairment, including an eGFR below 30 ml/min/1.73 m². Mounjaro has different rules and requires caution where evidence is limited.

TSH helps assess thyroid function but needs interpretation alongside symptoms, with further investigation where indicated. ALT and AST may prompt liver investigations but do not establish the cause of an abnormality on their own. Uric acid can inform gout risk assessment, and a blood count is useful when anaemia or heavy periods are a concern. The doctor decides whether previous results remain relevant; six-month-old tests may not always suffice. Ordered tests can be done in Elbląg or nearer home.

Prepare a list of all medicines and supplements, including hormone tablets and patches. Packs or photographs can help. Steroids, insulin, sulfonylureas and some antiepileptic and antidepressant medicines can contribute to weight gain. During treatment and substantial weight change, the doctor assesses whether thyroid tests are needed for someone taking levothyroxine and whether blood pressure medication needs adjustment. Do not change doses yourself.

When is a bone density scan, mammogram or gynaecology consultation needed?

A broad hormone panel is not routine for everyone with obesity. Suspected conditions such as Cushing's syndrome call for targeted investigation. After menopause we also ask about breast screening, bleeding and bone health. The NFZ programme usually provides screening mammography every 24 months for women aged 45 to 74 without a referral; separate 12-month pathways exist after breast cancer treatment. A breast lump needs investigation without waiting for the next screening round. Any postmenopausal bleeding needs prompt gynaecological assessment.

A fracture after minor trauma, long-term steroids, a family history of osteoporosis or menopause before age 45 are reasons to assess fracture risk. The doctor decides whether and when bone densitometry is needed. Its result informs bone care alongside nutrition, function and other conditions. It does not by itself determine the number of workouts or supplement doses.

Menopause brings changes in body composition, but weight gain has other causes too. Abdominal fat becomes more common, while loss of lean mass and bone density deserve attention during weight loss. We also consider menopausal symptoms, hormone treatment, cancer prevention and urinary incontinence.

What does menopause change in body composition, and why is weight alone not enough?

The 2019 SWAN study followed the same women over years using DXA to measure body composition. During the menopausal transition, the average rate of fat gain doubled and lean mass began to decline. These changes continued until about 2 years after the last menstrual period before levelling off. Overall weight gain did not accelerate. Lean mass includes muscle; this does not mean every woman loses the same amount of muscle or stores all new fat around her abdomen.

PTLO describes studies in which changing habits during this period helped limit weight gain, including over five years of follow-up. A 48-year-old woman with a BMI of 26 and a waist of 88 cm does not need to wait until her BMI exceeds 30 to seek advice, change her diet or begin suitable strengthening exercises. Medication is considered when the product's indications are met.

Does menopausal hormone therapy cause weight loss, and can it be combined with semaglutide?

Menopausal hormone therapy may favourably affect fat distribution, but PTLO does not recommend it as treatment for abdominal obesity. It is used, among other reasons, to relieve hot flushes and other troublesome symptoms. The 2024 Mayo analysis included 106 postmenopausal women treated with semaglutide: 16 used hormones and 90 did not. Mean weight loss after a year was 16% and 12%, respectively; the hormone group also more often reached 5% and 10% weight loss.

This was a small retrospective analysis of records. It shows an association, not proof that hormones improve semaglutide's effectiveness. The Spanish Menopause Society's 2026 statement found these observations insufficient to justify starting hormones to lose more weight. Combined treatment may be considered after reviewing the products and the patient's health. Tell the clinicians managing your treatment about worsening menopausal symptoms or new problems; an existing hormone plan is not automatically appropriate indefinitely.

How do we limit muscle and bone density loss during weight loss after menopause?

Substantial weight loss can be accompanied by reduced bone density. A separate SWAN cohort analysis by Shieh and colleagues, published in 2023 and including 539 women, linked greater lean mass loss and fat gain to greater subsequent fracture risk. This is an observed association, not proof that a particular exercise programme prevents every fracture.

A 2024 Danish secondary analysis of a randomised trial assessed 195 adults with obesity. After an initial 800 kcal-per-day diet, participants received liraglutide, an exercise programme, both, or placebo for a year. Exercise included aerobic and strengthening activities. Hip and spine bone density fell more with liraglutide alone than with exercise alone, despite similar weight loss. In the combined group, which lost the most weight, there was no significant difference in bone density at these sites compared with placebo. This does not mean there was no decline from baseline. The trial did not study only postmenopausal women or every incretin medicine.

Strengthening activity and adequate nutrition help limit muscle loss. Twice-weekly training and 1 to 1.5 g of protein per kilogram of ideal body weight per day, spread across meals, may be considered. We tailor this to function, nutritional status and medical conditions, particularly kidney disease. The doctor assesses the need for vitamin D, calcium, densitometry and osteoporosis treatment; it is not the same package for every patient.

How is obesity linked to female cancers and urinary incontinence?

Obesity increases the risk of endometrial cancer and breast cancer after menopause. A 2008 meta-analysis covering 141 observational research articles linked a 5 kg/m² higher BMI to 59% higher relative endometrial cancer risk. This is not a rise of 59 percentage points or proof that losing weight reverses the risk in the same proportion. Fat tissue contributes to oestrogen production after menopause; other metabolic mechanisms also matter. These findings cannot identify a single cause of an individual woman's cancer. An association between BMI and cancer incidence is not randomised evidence that a specified weight loss prevents cancer.

We therefore ask about mammography and refer women with postmenopausal spotting to a gynaecologist. Screening does not replace investigation of symptoms. A palpable lump or bleeding should not wait until weight loss treatment is finished.

PRIDE enrolled 338 women with overweight or obesity, averaging 53 years of age, who had at least 10 urinary incontinence episodes a week. They were randomly assigned to a six-month weight-loss programme or information sessions. In the programme group weight fell by an average of 8% and total incontinence episodes by 47%; episodes in the control group fell by 28%. In the subtype analysis, the significant advantage concerned stress incontinence. This does not mean urgency symptoms did not improve at all. PTLO gives 5 to 10% weight loss as a treatment goal for incontinence. We assess benefit individually; pelvic floor exercises and gynaecological or urological assessment may be needed during treatment too.

GLP-1 and GIP are gut hormones involved in the response to a meal. Semaglutide and liraglutide act on GLP-1 receptors; tirzepatide acts on GIP and GLP-1 receptors. These medicines can reduce appetite and make it easier to eat less, and they also affect stomach emptying. Satiety and treatment effects vary. Injectable semaglutide and tirzepatide are used weekly, liraglutide daily. Saxenda doses increase at intervals of at least one week. Mounjaro starts at 2.5 mg weekly, moving to 5 mg after four weeks; further 2.5 mg increases are made if needed after at least four weeks on the current dose.

What results did trials show, and when do we assess effectiveness?

In STEP 1, semaglutide 2.4 mg reduced mean body weight by 14.9% over 68 weeks, versus 2.4% with placebo. In SURMOUNT-1, tirzepatide 15 mg produced a 20.9% reduction over 72 weeks, versus 3.1% with placebo. In SCALE, liraglutide 3 mg produced an average loss of 8.4 kg over 56 weeks, versus 2.8 kg with placebo. These were separate trials with different populations, doses and durations, not a direct ranking of the medicines. Participants also received lifestyle support.

Applying 14.9% and 20.9% to 90 kg gives 13.41 kg and 18.81 kg. This only illustrates averages; it is not a prediction for a patient or a result after exactly one year. Fewer studies specifically concern postmenopausal women, and some evidence is observational. The doctor assesses effect, tolerability and nutrition according to the product. In adults, Saxenda is stopped if at least 5% of initial weight has not been lost after 12 weeks on 3 mg; Mysimba is assessed after 16 weeks of treatment and Xenical after 12 weeks. These are not universal rules for all medicines.

What happens to weight after medication stops?

In a subgroup of the STEP 1 extension, participants regained about two thirds of their lost weight within a year after semaglutide and the lifestyle intervention stopped. Benefits in glucose, blood pressure and other measures largely moved back towards baseline. This does not show that gradual dose reduction prevents regain.

Continuing or stopping treatment depends on effectiveness, safety and the patient's needs. We agree on monitoring weight, nutrition and activity after stopping as well. Strengthening exercise supports muscle health but does not guarantee weight maintenance without medication. Regain is a reason for reassessment, not for restarting a dose yourself.

We discuss five medicines used for obesity: Wegovy, Mounjaro, Saxenda, Mysimba and Xenical. This is not an exhaustive market list. Ozempic and Rybelsus contain semaglutide, and Victoza contains liraglutide, but their indications concern type 2 diabetes. The same active substance does not mean identical indications, doses or reimbursement rules. Off-label use is a separate medical decision, rather than a synonym for a legal ban on prescribing.

What separates Wegovy from Ozempic beyond the dose, and why do we prescribe Wegovy?

Obesity treatment is selected according to the product's indications and the patient's health, taking diabetes management into account where relevant. Ozempic has doses up to 2 mg and indications in type 2 diabetes. Injectable Wegovy is indicated for weight management; in addition to 2.4 mg, current product information describes 7.2 mg for selected adults with an initial BMI of at least 30 after at least four weeks on 2.4 mg, if needed. European documentation also includes oral Wegovy for adults. Authorisation does not establish the availability of a particular pack in a Polish pharmacy.

Saxenda 3 mg is indicated for obesity, while Victoza up to 1.8 mg is indicated for diabetes. Mounjaro, or tirzepatide, has indications in both conditions. Adult maintenance doses are 5, 10 or 15 mg weekly; 2.5 mg is a starting dose. The medicine and dose are chosen by considering benefits, tolerability and contraindications, not names alone.

What does each of the five medicines cost per month at the pharmacy?

These five products were not found in the reimbursement list effective from 1 July 2026. Medication costs therefore need to be budgeted separately from the price of the programme. Ask a pharmacy for the current price and availability of the exact brand, dose and pack size. Monthly spending depends on consumption: a pack price or another liraglutide brand's price is not automatically Saxenda's monthly cost. Prices for Wegovy doses up to 2.4 mg do not describe the cost of 7.2 mg or tablets. Reimbursement eligibility for diabetes or other indications is assessed separately.

When do we consider Mysimba or Xenical?

Mysimba combines naltrexone and bupropion, acting on satiety and reward pathways. In COR-I, average weight loss over 56 weeks was 6.1%, versus 1.3% with placebo. Treatment stops if at least 5% of initial weight has not been lost after 16 weeks. Thereafter, effectiveness, maintenance of benefit and cardiovascular safety need reassessment at least annually. Contraindications include uncontrolled hypertension, epilepsy, bipolar disorder, a history of bulimia or anorexia, opioid treatment and acute alcohol withdrawal. Mysimba is not recommended over age 75 and requires caution over 65. Emotional eating may inform the assessment but does not by itself determine the choice.

Xenical contains orlistat 120 mg in capsules and reduces absorption of about one third of dietary fat. Trials showed about 3 kg more weight loss than placebo after a year. Fatty meals increase the risk of oily stools, so dietary advice matters. Its own BMI thresholds and contraindications apply; mild overweight alone is insufficient. Treatment stops if at least 5% of pretreatment weight has not been lost after 12 weeks.

Common adverse effects include nausea, vomiting, diarrhoea and constipation, especially during dose escalation. Slower stomach emptying can make large or fatty meals harder to tolerate. Smaller portions and adapting food and fluids to symptoms may help. The doctor reviews dosing if tolerability is poor. In STEP 1, 4.5% of semaglutide recipients stopped because of gastrointestinal symptoms. Persistent vomiting, inability to drink or deterioration require prompt medical help. Do not wait a full day when there are signs of dehydration; diuretics and kidney disease also need consideration.

Contraindications, precautions and thyroid monitoring

Obesity medicines are not used during pregnancy. Wegovy and Saxenda should not be used during breastfeeding; current Mounjaro information allows individual consideration. Previous pancreatitis calls for caution and assessment, rather than a blanket absolute ban on every product. Discuss thyroid disease, a family history of cancer, heart failure and kidney or liver disease before treatment. They do not form a single contraindication list for the whole group.

Wegovy and Saxenda are not recommended in severe kidney or liver impairment. Mounjaro does not require dose adjustment solely for these reasons, but evidence in severe disease is limited and caution is needed. Saxenda is not recommended from 75; evidence for Wegovy and Mounjaro is limited from 85. If a patient uses insulin or a sulfonylurea, the doctor assesses dose adjustment based on glucose levels to reduce hypoglycaemia risk. Blood pressure medicines are adjusted to readings, not automatically after the first injection.

During treatment and substantial weight change, the doctor may request thyroid tests and review the levothyroxine dose. The reported 33% increase in T4 exposure concerned oral semaglutide and should not be attributed to injections. Do not change thyroid hormone doses yourself. Before anaesthesia or deep sedation, tell the procedural team about your obesity medicine. Because it affects stomach emptying, that team determines the preparation plan.

Symptoms requiring urgent medical attention

Severe, persistent upper abdominal pain, particularly radiating to the back with vomiting, may indicate acute pancreatitis. If this is suspected, stop the medicine and seek urgent medical care. Pain under the right ribs with fever or jaundice also needs urgent assessment, including for biliary disease. Gallstones were reported in 1.6% of people treated in semaglutide trials. A symptom alone is not a diagnosis.

Sudden deterioration or loss of vision requires immediate ophthalmological assessment. In 2025, EMA recognised NAION, an ischaemic injury to the optic nerve, as a very rare adverse effect of semaglutide. Do not wait for a routine follow-up. Palpitations, trembling hands, sweating and insomnia in someone taking levothyroxine need evaluation of thyroid function and other possible causes. Urgency depends on severity; reducing the dose yourself or waiting for routine TSH testing is not sufficient.

How can you buy obesity medicines safely?

Buy from a legal pharmacy, where a pharmacist verifies the pack through the safety system. A printed batch number alone does not prove authenticity. In 2023, Poland's GIF warned about falsified Ozempic pens. Severe hypoglycaemia after counterfeit pens containing insulin was reported in Austria. Classified-ad products and vials sold as research peptides offer no assurance of composition, quality or sterility. The doctor issues a prescription after assessment, and dose changes are agreed with them.

A dietitian tailors food intake to energy needs, medical conditions, activity and tolerability. PTLO guidance commonly considers a daily deficit of 500 to 750 kcal, but this is not a fixed target for every woman. After menopause, current energy needs matter more than returning to portions from twenty years ago. Protein may be planned at 1 to 1.5 g per kilogram of ideal body weight daily across meals; kidney disease and malnutrition need individual assessment.

As medication reduces appetite, we check that food intake is adequate and muscle is not being lost too. A day on just one sandwich calls for reviewing meals and treatment tolerability. We discuss calcium sources, fluids and whether vitamin D or other supplements are needed, including their dose. Strengthening exercises with bands or dumbbells can be adapted to function; two sessions a week may be a goal if health permits.

How does a psychodietitian address evening stress eating?

An appetite-reducing medicine does not replace work on emotional eating. Hot flushes can disrupt sleep, and poor sleep can make appetite harder to manage. A psychodietitian helps identify situations where food is sought without hunger and plan an alternative response: a short walk, calling someone close or eating a planned evening meal. We also ask about loss of control over eating. A single feature does not diagnose binge eating; referral for an eating-disorder assessment may be needed. Fear of regaining weight after earlier diets can also need support.

Alcohol provides energy that needs to be included in a meal plan: ethanol supplies 7 kcal per gram, while wine calories also depend on portion size and sugar content. Regular drinking can reduce the planned energy deficit, disrupt sleep and worsen gastrointestinal symptoms. In someone using insulin, it also increases hypoglycaemia risk, and symptoms can be mistaken for intoxication. We do not assume every patient experiences alcohol differently after an injection; discuss how much and how often you drink with the doctor.

Mysimba contains naltrexone and bupropion. Naltrexone is also used for alcohol dependence, but the combination for obesity has a different indication and safety rules. Alcohol should be minimised with Mysimba; acute alcohol withdrawal is a contraindication because of seizure risk. Someone with dependence should arrange safe withdrawal with a clinician.

A 2025 phase two trial is an example of preliminary semaglutide research in alcohol dependence: 48 participants were followed for 9 weeks, with treated participants reporting less craving and fewer drinks on drinking days. This is not an authorised semaglutide indication. For daily drinking or loss of control, we help plan alcoholism treatment in Elbląg. Obesity care needs coordination with addiction therapy, as drinking can interfere with recommendations and medication safety.

The initial and final doctor consultations and the two psychologist consultations take place by video. The five monthly medical reviews use the data in the app and do not involve a call. The doctor assesses the weight, waist circumference and blood pressure measured by the patient at home. They ask about symptoms including incontinence, hot flushes and joint pain. Skin changes or abdominal symptoms may need further investigation.

Before the initial consultation, provide previous results, a medicine list and your own measurements. If an in-person examination is needed before choosing treatment, the doctor decides where it should be done. Reception can provide available dietetic and psychodietetic support appointments. New symptoms may require an in-person examination, while severe abdominal pain, sudden visual deterioration or substantial bleeding need urgent help rather than waiting for a routine check-up.

NFZ-funded care can start with a primary care doctor, who assesses health, orders tests within their remit and refers when indicated. The mammography programme usually covers screening every 24 months for women aged 45 to 74 without referral. Bone densitometry and bariatric surgery require eligibility assessment and the appropriate care pathway; a private recommendation does not guarantee funding for every test.

Access to a dietitian in coordinated care depends on programme eligibility and the participating practice. Moje Zdrowie also includes dietary advice, which may be given by a dietitian or another authorised team member. This does not mean full individual diet therapy is available in every primary care practice. Ask your practice about its arrangements. Hormone treatment for menopausal symptoms can be managed by a gynaecologist through NFZ or privately.

The obesity treatment programme at Nasz Gabinet costs PLN 1,799 for 6 months. The programme includes two online consultations with a psychologist; dietitian and psychodietitian consultations are not included. Medicines are bought separately from a pharmacy. Appointment funding does not itself determine the medicine price: reimbursement depends on the product, indication and eligibility. Discuss test costs and the scope of further care when planning treatment.

We refer for bariatric assessment after considering weight, other conditions and previous treatment. The 2025 Polish consensus indicates BMI at least 35 regardless of overt obesity-related disease, with surgery also considered at BMI 30 to 34.9 in type 2 diabetes inadequately controlled despite treatment. The 2022 ASMBS/IFSO recommendations also expanded indications, including individual consideration at BMI 30 to 34.9. Not every case requires exhausting all methods over a fixed period. The centre makes the final eligibility and funding assessment; clinical guidelines are not identical to NFZ criteria.

Older age alone does not exclude surgery. Function, frailty, nutrition and medical conditions matter. The team also assesses mental health, eating disorders, addiction and preparation needs. Not every diagnosis of depression or binge eating carries the same reason for postponement.

The Association of Polish Surgeons list reviewed in September 2026 includes three centres in Warmia and Masuria, in Ełk, Olsztyn and Bartoszyce, and six in Pomerania, including three in Gdańsk. The list does not confirm current NFZ contracts or appointments. Olsztyn and Gdańsk are possible destinations, not the only options; check the scope of care and postoperative reviews before booking. The KOS-BAR pilot ended on 30 June 2026. Further care remains available under general guaranteed-service arrangements; ending the pilot did not end NFZ-funded surgery.

Preparation, including nutrition and any preoperative weight loss, follows the centre's recommendations. Bone assessment is particularly relevant after menopause: surgery can affect bone density and nutrient absorption. Densitometry and repeat timing depend on risk. Long-term monitoring and supplements are needed after surgery, tailored to the procedure and results, including calcium, vitamin D, B12 and iron. Doses and testing intervals are not identical for every patient.

When pregnancy is planned, we discuss the Association of Polish Surgeons recommendation to wait at least 24 months after surgery; the centre and gynaecologist agree on an individual plan. Fertility is not judged simply by whether someone is under fifty. Medication can also be considered for postoperative regain. PTLO cites an observation of 207 people, with one-year weight loss of 12.9% on semaglutide and 8.8% on liraglutide. These are observational results, not a randomised comparison or an individual guarantee.

People from Braniewo, Frombork, Tolkmicko, Pasłęk, Młynary, Morąg, Ostróda and Iława, and from Malbork, Nowy Dwór Gdański, Sztum, Dzierzgoń, Prabuty and Kwidzyn can have their programme consultations without leaving home. The consultations take place in the app, and blood tests can be done closer to home.

Mammography can be arranged at a suitable unit or mobile service under programme rules; a lump requires separate investigation. Provide the date and result of your last test. If you see a gynaecologist in Malbork, Braniewo or elsewhere, we discuss cooperation and agree with you how to share the necessary records on the medicine and dose.

NFZ-funded obesity treatment in Elbląg and the region can begin in primary care. Your GP assesses related conditions and referral needs. For type 2 diabetes, a diabetes clinic may be an appropriate pathway. Before booking a specialist clinic, check its scope, accepted ages and current availability. The name "metabolic clinic" does not establish that it treats adult obesity.

The Olsztyn children's hospital clinic entry covers children and adolescents, so it does not describe access for postmenopausal women. A metabolic clinic in the Tricity may also have a different remit, such as phenylketonuria. The NFZ information service helps locate care, but acceptance criteria and appointments should be confirmed with the facility; average waiting time is not an appointment date for a new patient. In our online programme, consultations are booked in the Nasz Gabinet app. Medicine costs and any reimbursement depend on the product and indication, separately from appointment funding.